A study by The Prostate Cancer Transatlantic Consortium (CaPTC) utilizing whole exome sequencing to determine genetic variants in Nigerian patients with advanced prostate cancer identified high frequencies of mutations in the BRCA1, BRCA2, APC, and ATM genes. This evidence concerns the gene BRCA2 and prostate cancer.